Dan Paterson has wasted no time signing off on his first deal as CEO of Verastem Oncology. One month into the job, Paterson has put together a financial package worth up to $625.5 million to bag options on three GenFleet Therapeutics programs targeting cancers driven by the RAS pathway.Paterson stepped up to the CEO position […]
